Drug Trial Radar · NCT05366478
A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Aug 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
May 30, 2022
Primary completion
May 30, 2024
Study completion May 30, 2029
Sponsor
- Lead sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 9, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, exploratory study to evaluate safety and efficacy of LM103 Injection in patients with advanced solid tumors. The purpose of this study is to evaluate the safety and tolerability, antitumor activity and immunoreactivity.
Conditions
- Melanoma
- Non Small Cell Lung Cancer
- Cervical Carcinoma
Interventions
Autologous tumor infiltrating lymphocytes (TILs)Drug
A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients will be infused with LM103 Injection followed by IL-2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of adverse events (AEs)Time frame: Up to 1 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Beichen Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.